Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...